Gujarat: PM Modi reviews vaccine development at Zydus Cadila facility

AHMEDABAD: Prime Minister Narendra Modi on Saturday began his three-city visit to review coronavirus vaccine development work by going to pharma major Zydus Cadila’s manufacturing facility near Ahmedabad. Wearing a PPE kit, Modi reviewed the vaccine development process at the Zydus Cadila research centre in Changodar industrial area, over 20 km from Ahmedabad.

After his arrival at Ahmedabad airport from Delhi shortly after 9 am, Modi flew to the Zydus Cadila plant and held discussions with the promoters and executives of the company, an official said.

Modi spent over an hour at the plant, before leaving for the airport, from where will fly to Hyderabad.

Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August.

In Hyderabad, Modi is scheduled to visit vaccine maker Bharat Biotech’s facility.

After landing at Hakimpet Air Force station, Modi will reach Bharat Biotech’s facility at Genome Valley at 1.30 pm. The facility is around 50 km from Hyderabad.

Bharat Biotech’s Covaxin is undergoing phase-3 trials.

After his hour-long visit to the facility, the PM will proceed to Pune, where he will visit the Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and the Oxford University for the vaccine.

The prime minister will reach Serum Institute campus around 4.30 pm, an official said.

Modi’s hour-long visit to SII is aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanism, he said.

The PM will fly back to Delhi in the evening, the official said.

  • Related Posts

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

    Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

    Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore